Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Increased dysbindin-1B isoform expression in schizophrenia and its propensity in aggresome formation.

Xu Y, Sun Y, Ye H, Zhu L, Liu J, Wu X, Wang L, He T, Shen Y, Wu JY, Xu Q.

Cell Discov. 2015 Nov 10;1:15032. doi: 10.1038/celldisc.2015.32. eCollection 2015.

2.

Expression of the Longest RGS4 Splice Variant in the Prefrontal Cortex Is Associated with Single Nucleotide Polymorphisms in Schizophrenia Patients.

Ding L, Styblo M, Drobná Z, Hegde AN.

Front Psychiatry. 2016 Feb 29;7:26. doi: 10.3389/fpsyt.2016.00026. eCollection 2016.

3.

Animal Models of Psychosis: Current State and Future Directions.

Forrest AD, Coto CA, Siegel SJ.

Curr Behav Neurosci Rep. 2014 Jun 1;1(2):100-116.

4.

Personalized medicine in psychiatry: problems and promises.

Ozomaro U, Wahlestedt C, Nemeroff CB.

BMC Med. 2013 May 16;11:132. doi: 10.1186/1741-7015-11-132. Review.

5.

Systems genetics of alcoholism.

Sloan CD, Sayarath V, Moore JH.

Alcohol Res Health. 2008;31(1):14-25. Review.

6.

Expression of the G72/G30 gene in transgenic mice induces behavioral changes.

Cheng L, Hattori E, Nakajima A, Woehrle NS, Opal MD, Zhang C, Grennan K, Dulawa SC, Tang YP, Gershon ES, Liu C.

Mol Psychiatry. 2014 Feb;19(2):175-83. doi: 10.1038/mp.2012.185. Epub 2013 Jan 22.

7.

Ablation of Mrds1/Ofcc1 induces hyper-γ-glutamyl transpeptidasemia without abnormal head development and schizophrenia-relevant behaviors in mice.

Ohnishi T, Yamada K, Watanabe A, Ohba H, Sakaguchi T, Honma Y, Iwayama Y, Toyota T, Maekawa M, Watanabe K, Detera-Wadleigh SD, Wakana S, Yoshikawa T.

PLoS One. 2011;6(12):e29499. doi: 10.1371/journal.pone.0029499. Epub 2011 Dec 29.

8.

Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia.

Carlson GC, Talbot K, Halene TB, Gandal MJ, Kazi HA, Schlosser L, Phung QH, Gur RE, Arnold SE, Siegel SJ.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):E962-70. doi: 10.1073/pnas.1109625108. Epub 2011 Oct 3.

9.

D-amino acid oxidase activity is inhibited by an interaction with bassoon protein at the presynaptic active zone.

Popiolek M, Ross JF, Charych E, Chanda P, Gundelfinger ED, Moss SJ, Brandon NJ, Pausch MH.

J Biol Chem. 2011 Aug 19;286(33):28867-75. doi: 10.1074/jbc.M111.262063. Epub 2011 Jun 23.

10.

The association of schizophrenia risk D-amino acid oxidase polymorphisms with sensorimotor gating, working memory and personality in healthy males.

Roussos P, Giakoumaki SG, Adamaki E, Georgakopoulos A, Robakis NK, Bitsios P.

Neuropsychopharmacology. 2011 Jul;36(8):1677-88. doi: 10.1038/npp.2011.49. Epub 2011 Apr 6. Erratum in: Neuropsychopharmacology. 2011 Oct;36(11):2370. Anastasios, Georgakopoulos [corrected to Georgakopoulos, Anastasios]; Nikos, Robakis K [corrected to Robakis, Nikos K].

11.

The first decade and beyond of transcriptional profiling in schizophrenia.

Sequeira PA, Martin MV, Vawter MP.

Neurobiol Dis. 2012 Jan;45(1):23-36. doi: 10.1016/j.nbd.2011.03.001. Epub 2011 Mar 8. Review.

12.

Contribution of nonprimate animal models in understanding the etiology of schizophrenia.

Lazar NL, Neufeld RW, Cain DP.

J Psychiatry Neurosci. 2011 Jul;36(4):E5-29. doi: 10.1503/jpn.100054. Review.

13.

Biological validation of increased schizophrenia risk with NRG1, ERBB4, and AKT1 epistasis via functional neuroimaging in healthy controls.

Nicodemus KK, Law AJ, Radulescu E, Luna A, Kolachana B, Vakkalanka R, Rujescu D, Giegling I, Straub RE, McGee K, Gold B, Dean M, Muglia P, Callicott JH, Tan HY, Weinberger DR.

Arch Gen Psychiatry. 2010 Oct;67(10):991-1001. doi: 10.1001/archgenpsychiatry.2010.117.

14.

A polymorphism in the dysbindin gene (DTNBP1) associated with multiple psychiatric disorders including schizophrenia.

Voisey J, Swagell CD, Hughes IP, Connor JP, Lawford BR, Young RM, Morris CP.

Behav Brain Funct. 2010 Jul 9;6:41. doi: 10.1186/1744-9081-6-41.

15.

Nature and nurture in neuropsychiatric genetics: where do we stand?

Dick DM, Riley B, Kendler KS.

Dialogues Clin Neurosci. 2010;12(1):7-23. Review.

16.

The dystrobrevin binding protein 1 (DTNBP1) gene is associated with schizophrenia in the Irish Case Control Study of Schizophrenia (ICCSS) sample.

Riley B, Kuo PH, Maher BS, Fanous AH, Sun J, Wormley B, O'Neill FA, Walsh D, Zhao Z, Kendler KS.

Schizophr Res. 2009 Dec;115(2-3):245-53. doi: 10.1016/j.schres.2009.09.008. Epub 2009 Oct 2.

17.

The neurobiology of D-amino acid oxidase and its involvement in schizophrenia.

Verrall L, Burnet PW, Betts JF, Harrison PJ.

Mol Psychiatry. 2010 Feb;15(2):122-37. doi: 10.1038/mp.2009.99. Epub 2009 Sep 29. Review.

18.

No association of dysbindin with symptom factors of schizophrenia in an Irish case-control sample.

Bergen SE, Fanous AH, Kuo PH, Wormley BK, O'Neill FA, Walsh D, Riley BP, Kendler KS.

Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):700-5. doi: 10.1002/ajmg.b.31029.

19.

DTNBP1 is associated with imaging phenotypes in schizophrenia.

Narr KL, Szeszko PR, Lencz T, Woods RP, Hamilton LS, Phillips O, Robinson D, Burdick KE, DeRosse P, Kucherlapati R, Thompson PM, Toga AW, Malhotra AK, Bilder RM.

Hum Brain Mapp. 2009 Nov;30(11):3783-94. doi: 10.1002/hbm.20806.

20.

Dysbindin-1, a schizophrenia-related protein, functionally interacts with the DNA- dependent protein kinase complex in an isoform-dependent manner.

Oyama S, Yamakawa H, Sasagawa N, Hosoi Y, Futai E, Ishiura S.

PLoS One. 2009;4(1):e4199. doi: 10.1371/journal.pone.0004199. Epub 2009 Jan 14.

Items per page

Supplemental Content

Write to the Help Desk